Triglyceride-rich lipoprotein

lipoprotein

Triglyceride-rich lipoprotein accumulation in subendothelium initiates lipid oxidation and atherogenic inflammation driving atherothrombotic MI.

Pathway placement

Cascade stepLipid retention & oxidation

Confidencehigh

RationaleCausal atherogenic remnant particles; promote atherosclerosis and vascular toxicity via subendothelial retention.

Also acts inVascular inflammation

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-5.3

Confounder panel (Type-II drivers)

No confounder evidence retrieved.

Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Specialized reference method

Specimen

Serum or plasma (EDTA)

Collection tube

K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)

Method / principle

NMR lipoprotein particle analysis or density-gradient ultracentrifugation

Reagent / substrate

No chemical reagent — NMR spectral deconvolution of lipid methyl signals (or ultracentrifugal separation by density)

Platform

NMR (LabCorp NMR LipoProfile) / analytical ultracentrifuge

Turnaround · availability

Send-out · Specialized reference lab